Now showing items 1-1 of 1

    • Single-inhaler triple therapy in symptomatic COPD patients: FULFIL subgroup analyses. 

      Halpin, David M; Birk, R.; Brealey, N.; Criner, G.J.; Dransfield, M. T.; Hilton, E.; Lomas, D. A.; Zhu, C-Q; Lipson, D. A. (European Respiratory Society, 2018-04)
      Triple inhaled corticosteroid (ICS)/long-acting muscarinic antagonist (LAMA)/long-acting β2-agonist (LABA) therapy is recommended for symptomatic patients with chronic obstructive pulmonary disease (COPD) and at risk of ...